Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$1.22 +5.2%	$1.05	$0.66 ▼ $5.92	$139.82M	2.32	2.23 million shs	1.40 million shs
MNMD Mind Medicine (MindMed)	$7.14 -2.2%	$6.22	$4.70 ▼ $10.44	$538.13M	2.52	1.39 million shs	1.51 million shs
PRTC PureTech Health	$17.42 -4.3%	$17.21	$13.30 ▼ $32.98	$418.29M	1.14	4,706 shs	4,294 shs
SAGE Sage Therapeutics	$6.52 -0.2%	$7.26	$4.62 ▼ $13.47	$408.29M	0.2	1.20 million shs	806,723 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	+5.17%	-2.40%	-4.69%	+5.17%	-65.34%
MNMD Mind Medicine (MindMed)	-2.19%	-6.05%	+14.61%	+4.69%	-13.24%
PRTC PureTech Health	-4.31%	-0.03%	+0.90%	-6.27%	-40.46%
SAGE Sage Therapeutics	-0.15%	-8.56%	-16.30%	-9.07%	-44.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FATE Fate Therapeutics	4.4873 of 5 stars	4.1	3.0	4.7	3.0	1.7	0.6
MNMD Mind Medicine (MindMed)	1.9315 of 5 stars	3.7	1.0	0.0	3.0	0.8	0.6
PRTC PureTech Health	2.0513 of 5 stars	3.8	4.0	0.0	2.3	0.0	0.0
SAGE Sage Therapeutics	3.7426 of 5 stars	3.0	2.0	4.0	2.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.22	Hold	$4.14	239.58% Upside
MNMD Mind Medicine (MindMed)	3.31	Buy	$25.11	251.70% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	158.40% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.81	35.16% Upside

Current Analyst Ratings Breakdown

Latest FATE, PRTC, SAGE, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/11/2025	SAGE Sage Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$5.00
3/7/2025	MNMD Mind Medicine (MindMed)	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$27.00 ➝ $16.00
3/7/2025	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
3/6/2025	FATE Fate Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$5.00 ➝ $3.00
3/6/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$5.00 ➝ $4.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$13.34M	10.48	N/A	N/A	$3.74 per share	0.33
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A
PRTC PureTech Health	$4.32M	96.94	N/A	N/A	$16.94 per share	1.03
SAGE Sage Therapeutics	$47.40M	8.61	N/A	N/A	$7.56 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$160.93M	-$1.49	N/A	N/A	N/A	-1,325.43%	-45.88%	-33.95%	8/12/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$95.73M	-$1.29	N/A	N/A	N/A	N/A	-47.56%	-35.55%	8/12/2025 (Estimated)
PRTC PureTech Health	-$65.70M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-971.50%	-68.18%	-60.84%	7/30/2025 (Estimated)

Latest FATE, PRTC, SAGE, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
3/6/2025	Q4 2024	MNMD Mind Medicine (MindMed)	-$0.33	-$0.41	-$0.08	-$0.41	N/A	N/A
3/5/2025	Q4 2024	FATE Fate Therapeutics	-$0.44	-$0.31	+$0.13	-$0.44	$1.57 million	$1.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	8.29	8.29
MNMD Mind Medicine (MindMed)	0.09	9.00	9.00
PRTC PureTech Health	N/A	3.68	N/A
SAGE Sage Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
MNMD Mind Medicine (MindMed)	27.91%
PRTC PureTech Health	0.04%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	5.51%
MNMD Mind Medicine (MindMed)	2.45%
PRTC PureTech Health	5.30%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	114.60 million	108.20 million	Optionable
MNMD Mind Medicine (MindMed)	40	75.37 million	71.68 million	Optionable
PRTC PureTech Health	100	24.02 million	22.67 million	Not Optionable
SAGE Sage Therapeutics	690	62.62 million	58.10 million	Optionable

FATE, PRTC, SAGE, and MNMD Headlines

Recent News About These Companies

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation

May 27 at 10:00 AM | accessnewswire.com

136,723 Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) Purchased by Toronto Dominion Bank

May 27 at 4:15 AM | marketbeat.com

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Millennium Management LLC

May 27 at 3:38 AM | marketbeat.com

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 25 at 10:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect

May 22, 2025 | accessnewswire.com

Lazard Asset Management LLC Buys New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 22, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Buys 114,173 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 21, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation

May 20, 2025 | accessnewswire.com

Brokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) PT at $8.81

May 20, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Lowered to Sell Rating by StockNews.com

May 20, 2025 | americanbankingnews.com

Neuromodulation: rewiring healthcare?

May 19, 2025 | msn.com

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from Brokerages

May 19, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out

May 18, 2025 | accessnewswire.com

RTW Investments LP Lowers Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 18, 2025 | marketbeat.com

Jane Street Group LLC Raises Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 18, 2025 | marketbeat.com

Cubist Systematic Strategies LLC Acquires Shares of 152,726 Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 17, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Reduces Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 16, 2025 | marketbeat.com

Algert Global LLC Sells 104,738 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 16, 2025 | marketbeat.com

Sage Therapeutics Shareholder Sues Over Drug Prospect Claims

May 16, 2025 | news.bloomberglaw.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

May 15, 2025 | accessnewswire.com

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 13, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, PRTC, SAGE, and MNMD Company Descriptions

Fate Therapeutics NASDAQ:FATE

$1.22 +0.06 (+5.17%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.24 +0.02 (+1.23%)

As of 05/27/2025 05:47 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Mind Medicine (MindMed) NASDAQ:MNMD

$7.14 -0.16 (-2.19%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$7.19 +0.05 (+0.70%)

As of 05/27/2025 07:57 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

PureTech Health NASDAQ:PRTC

$17.42 -0.79 (-4.31%)

As of 05/27/2025 04:00 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Sage Therapeutics NASDAQ:SAGE

$6.52 -0.01 (-0.15%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$6.52 0.00 (-0.08%)

As of 05/27/2025 05:52 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time